Preclinical BioLineRx (BLRX) BL-8040 Data on AML is Encouraging - Roth Capital
Tweet Send to a Friend
Roth Capital affirms BioLineRx (Nasdq: BLRX) at Buy with a target price of $8 following a presentation of promising preclinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE